Outcome in Systemic Anaplastic Large Cell Lymphoma: Beyond ALK
10/08/12 • 8 min
The prognostic importance of ALK-protein expression was established over a decade ago. More recent studies emphasize that age is also an important driving force and in patients
The prognostic importance of ALK-protein expression was established over a decade ago. More recent studies emphasize that age is also an important driving force and in patients
Previous Episode
Should Gemtuzumab Ozogamicin Be Re-added to the Therapeutic Armamentarium for Acute Myeloid Leukemia?
Although gemtuzumab ozogamicin has been withdrawn from the marketplace, three randomized trials prompt review of that decision.
Next Episode
Informed Consent for Pediatric Phase I Cancer Trials: An End-of-Life Decision
Melissa Cousino and colleagues found that few parents understand the scientific purpose of phase I pediatric clinical trials.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/journal-of-clinical-oncology-jco-podcast-448/outcome-in-systemic-anaplastic-large-cell-lymphoma-beyond-alk-67159"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to outcome in systemic anaplastic large cell lymphoma: beyond alk on goodpods" style="width: 225px" /> </a>
Copy